tirzepatide and keto In adults with obesity but not diabetes, leads to significantly greater weight loss than semaglutide over 72 weeks, nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL tirzepatide ketosis Trial of +

60 MeissnerW.RemyP.GiordanaC.MaltteD.DerkinderenP.HoutoJ.et al (2024)

Q2: How long before I see results from GHK-Cu

Finerenone and other future therapeutic options for Alport syndrome

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea or cardiovascular disease)

Previously, these treatments required patients to self-administer injections on a regular basis, which could be a barrier to adherence for many individuals

Exposure to high temperatures (above the recommended limits) can cause the protein structure to denature or break down, reducing the medication's potency